{"success":true,"data":{"pressRelease":{"id":"125310","rtpr_id":"nBw5YlD1Sa","ticker":"ZURA","exchange":"NASDAQ","all_tickers":["ZURA"],"title":"Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Business Wire","published_at":"2026-08-21T23:57:00.069Z","article_body":"Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\n\nZura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a\nclinical-stage biotechnology company developing novel and differentiated\nmedicines to meaningfully improve the lives of patients with serious and\ndebilitating autoimmune and inflammatory diseases, today reported that on\nAugust 20, 2026, the Company granted inducement awards consisting of options\nto purchase up to 587,000 Class A Ordinary Shares (the “Options”) to\nthirteen newly hired employees. These awards were approved by the Compensation\nCommittee of the Company’s Board of Directors and granted outside the\nCompany’s 2023 Equity Incentive Plan, as amended (the “Plan”), as\ninducements material to the new employees’ employment, in accordance with\nNasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and\nconditions and other provisions set forth in the Company’s Plan and the\naward agreements thereunder.\n\nThe Options that were granted have an exercise price of $5.75 per Class A\nOrdinary Share, which is equal to the closing price of Zura’s Class A\nOrdinary Shares on August 20, 2026. The Options will each vest over four\nyears, with one-fourth (1/4th) of the shares subject to each Option vesting on\nthe one-year anniversary of the applicable vesting commencement date, and the\nremaining shares subject to each Option shall vest in equal quarterly\ninstallments thereafter, subject to the employee’s continuous service\nthrough such vesting date.\n\nABOUT ZURA\n\nZura is a clinical-stage, multi-asset immunology company developing novel\ndual-pathway antibodies for autoimmune and inflammatory diseases with unmet\nneed. Zura’s pipeline includes product candidates designed to target key\nmechanisms of immune system imbalance, with the goal of improving efficacy,\nsafety, and dosing convenience for patients.\n\nZura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in\ntwo Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis\nsuppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc).\nAdditional product candidates torudokimab (ZB-880) and crebankitug (ZB-168)\nhave completed Phase 1/1b studies and are being evaluated for their potential\nacross a range of autoimmune and inflammatory conditions.\n\nFor more information, please visit www.zurabio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zurabio.com&esheet=54593191&newsitemid=20260821914570&lan=en-US&anchor=www.zurabio.com&index=1&md5=ce4db19e9a14719154bf9a110051412c)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260821914570/en/\n(https://www.businesswire.com/news/home/20260821914570/en/)\n\nir@zurabio.com (mailto:ir@zurabio.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5YlD1Sa","title":"Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Business Wire","ticker":"ZURA","created":"2026-08-21T23:57:00.069Z","tickers":["ZURA"],"exchange":"NASDAQ","article_body":"Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\n\nZura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a\nclinical-stage biotechnology company developing novel and differentiated\nmedicines to meaningfully improve the lives of patients with serious and\ndebilitating autoimmune and inflammatory diseases, today reported that on\nAugust 20, 2026, the Company granted inducement awards consisting of options\nto purchase up to 587,000 Class A Ordinary Shares (the “Options”) to\nthirteen newly hired employees. These awards were approved by the Compensation\nCommittee of the Company’s Board of Directors and granted outside the\nCompany’s 2023 Equity Incentive Plan, as amended (the “Plan”), as\ninducements material to the new employees’ employment, in accordance with\nNasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and\nconditions and other provisions set forth in the Company’s Plan and the\naward agreements thereunder.\n\nThe Options that were granted have an exercise price of $5.75 per Class A\nOrdinary Share, which is equal to the closing price of Zura’s Class A\nOrdinary Shares on August 20, 2026. The Options will each vest over four\nyears, with one-fourth (1/4th) of the shares subject to each Option vesting on\nthe one-year anniversary of the applicable vesting commencement date, and the\nremaining shares subject to each Option shall vest in equal quarterly\ninstallments thereafter, subject to the employee’s continuous service\nthrough such vesting date.\n\nABOUT ZURA\n\nZura is a clinical-stage, multi-asset immunology company developing novel\ndual-pathway antibodies for autoimmune and inflammatory diseases with unmet\nneed. Zura’s pipeline includes product candidates designed to target key\nmechanisms of immune system imbalance, with the goal of improving efficacy,\nsafety, and dosing convenience for patients.\n\nZura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in\ntwo Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis\nsuppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc).\nAdditional product candidates torudokimab (ZB-880) and crebankitug (ZB-168)\nhave completed Phase 1/1b studies and are being evaluated for their potential\nacross a range of autoimmune and inflammatory conditions.\n\nFor more information, please visit www.zurabio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zurabio.com&esheet=54593191&newsitemid=20260821914570&lan=en-US&anchor=www.zurabio.com&index=1&md5=ce4db19e9a14719154bf9a110051412c)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260821914570/en/\n(https://www.businesswire.com/news/home/20260821914570/en/)\n\nir@zurabio.com (mailto:ir@zurabio.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-21T23:57:00.12592576Z","server_sent_at_ms":1787356620125},"received_at":"2026-08-21T23:57:00.177Z","source_url":"https://www.businesswire.com/news/home/20260821914570/en/"},"analysis":{"id":"114263","press_release_id":"125310","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"insider_transaction","narrative":"Zura Bio granted inducement awards consisting of options to purchase 587,000 Class A Ordinary Shares to thirteen newly hired employees.\n\nThe options have an exercise price of $5.75 per share, equal to the closing price on the grant date of August 20, 2026, and vest over four years.\n\nThese grants were approved by the Compensation Committee outside of the company's 2023 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine 8-K filing regarding new hire inducement grants."},"keyFigures":{"customDimensions":{"exercise_price":5.75,"options_granted":587000}},"quotedText":"","namedEntities":{"people":[],"products":["tibulizumab","ZB-106","torudokimab","ZB-880","crebankitug","ZB-168"],"companies":[{"name":"Zura Bio Limited","ticker":"ZURA"}],"dollarAmounts":[{"amount":"$5.75","context":"exercise price per Class A Ordinary Share"}]},"materialImpact":{"score":1,"reasoning":"Routine administrative disclosure of inducement stock options for 13 new employees. The grants are standard compensation measures and do not represent a material change in the company's financial position or business direction."},"tickerRelevance":{"others":[],"primary":"ZURA"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"compensation_disclosure","sectorWeight":"biotech"}},"event_type":"insider_transaction","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Zura Bio granted inducement awards consisting of options to purchase 587,000 Class A Ordinary Shares to thirteen newly hired employees.\n\nThe options have an exercise price of $5.75 per share, equal to the closing price on the grant date of August 20, 2026, and vest over four years.\n\nThese grants were approved by the Compensation Committee outside of the company's 2023 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).","key_figures":{"customDimensions":{"exercise_price":5.75,"options_granted":587000}},"named_entities":{"people":[],"products":["tibulizumab","ZB-106","torudokimab","ZB-880","crebankitug","ZB-168"],"companies":[{"name":"Zura Bio Limited","ticker":"ZURA"}],"dollarAmounts":[{"amount":"$5.75","context":"exercise price per Class A Ordinary Share"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-21T23:58:23.423Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"compensation_disclosure","sectorWeight":"biotech"}},"durationMs":83235,"modelName":"glm-4.7"}}